Pay in 4 interest-free payments of $5.32 Learn more
Ships within 48 hours · Estimated delivery Aug 13 - Aug 18
no completed Phase 1-3 human trials
The peptide's stability is another advantage for autoimmune research
These symptoms can sometimes discourage patients from continuing their treatment
Gender Disparities: Women comprise 56% of Medicaid enrollees with opioid use disorder Male enrollees 37% more likely to receive detoxification services Male enrollees 28% more likely to receive agonist medications (methadone, buprenorphine) Overall treatment rate: only 5% of enrollees with OUD receive any treatment Racial Disparities: White enrollees significantly more likely to receive detox and counseling services Non-White enrollees more frequently receive agonist medication treatments Only 4 in 10 Black Medicaid enrollees with OUD received medication treatment nationally Nearly 7 in 10 White enrollees with OUD received medication treatment nationally Addressing Disparities: Indiana implemented initiatives to reduce treatment gaps through policy reforms and expanded access programs
US$ 21.99
US$ 29.97
US$ 20.90
US$ 22.34
US$ 23.37
